Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Medical imaging solution provider VirtualScopics (VSCP) has expanded its strategic collaboration with North Carolina-based leading contract research organization (“CRO”) Pharmaceutical Product Development (“PPD”) Inc.

The companies have extended their partnership in clinical and medical imaging to now include a range of therapeutic areas such as oncology, central nervous system, cardiovascular, general medicine and medical devices.

VirtualScopics collaborated, in October 2010, with PPD Inc., to deliver a set of clinical and medical imaging solutions to help biopharmaceutical companies to make rapid decisions in developing oncology compounds. The scope of the collaboration was limited to oncology.

Medical imaging plays a significant role in drug development. The expanded alliance will enable the entities to offer biopharmaceutical companies with state-of-the-art, integrated and customized imaging technologies, which will help them to make important development decisions on their compounds. The pooling of the technologies and expertise of the two entities will enable their clients to accelerate their drug development programs.

VirtualScopics offers its imaging solutions to pharmaceutical, biotechnology and medical devices industries. The company provides a range of imaging software and applications that are used for image-based detection and measurement of anatomical structures and metabolic activity. VirtualScopics competes with BioClinica Inc and ICON plc (ICLR - Snapshot Report), among others.

The company remains committed to investing in infrastructure, services and additional technical and operational resources to address customer needs and broaden its global foothold.

Besides PPD, VirtualScopics also joined forces with Germany-based full-service CRO ABX-CRO in September 2010, which marked the union of two of the bellwethers in molecular imaging for the clinical trials of drugs and medical devices.

VirtualScopics’ third-quarter 2011 earnings of 2 cents a share beat the Zacks Consensus Estimate by a penny. The company’s profit (attributable to common stockholders) slid roughly 10.5% year over year, hurt by lower revenues which fell 9% year over year to $3.27 million.

VirtualScopics, in its third quarter call, noted that it has filed 510(k) with the U.S. Food and Drug Administration (“FDA”) for its first personalized medicine application. Based on tepid third quarter results, the company reduced its sales forecast for fiscal 2011. VirtualScopics envisions sales to pick up in first-half 2012, in part, driven by the PPD alliance.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%